Lidocaine Infusion Treatment for Subarachnoid Hemorrhage Headaches

Lidocaine Infusion As A Treatment Modality For Headache Following Non-Traumatic Subarachnoid Hemorrhage: A Prospective, Single-Center, Observational Cohort Study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06582810

Enrollment

Registered

2024-09-03

Start date

2025-01-31

Completion date

2028-07-01

Last updated

2026-07-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Headache, Subarachnoid; Hemorrhage, Nontraumatic

Keywords

Nontraumatic Subarachnoid Hemorrhage, Headache, Lidocaine Infusion

Brief summary

The goal of this observational study is to evaluate intravenous lidocaine efficacy and safety in treating headache following non-traumatic subarachnoid hemorrhage. Through this prospective analysis, the investigators hope to: 1. show that intravenous lidocaine infusion causes a clinically significant reduction in pain scores in patients with moderate/severe headache pain following non-traumatic subarachnoid hemorrhage; 2. show that intravenous lidocaine infusion is safe in treating headache following non-traumatic subarachnoid hemorrhage; 3. and report vasospasm prevalence in the cohort. Participants will receive lidocaine infusion as treatment for non-traumatic subarachnoid hemorrhage headache and provide pain scores (on a numeric pain scale) every two hours the patients are awake for a maximum of seven days. Monitoring for vasospasm will occur as part of the patients regular medical care.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients \> 18 years; * Have a favorable neurological status defined as Hunt and Hess score ≤ 3 (as it accounts for patient awareness); * Can communicate numeric pain scores; * Are diagnosed with non-traumatic subarachnoid hemorrhage

Exclusion criteria

* The patient is diagnosed with traumatic subarachnoid hemorrhage; * If the patient is \< 18 years of age; * If numeric pain scores could not be captured for \> 3 days of hospitalization; * If the patient had a prior aneurysm; * Chronic pain not associated with non-traumatic subarachnoid hemorrhage diagnosis; * A disability before the stroke (\> 2 on modified Rankin Scale score); * A Hunt and Hess score \> 3; * Contraindications to lidocaine (significant cardiac disease, arrhythmia, seizures, previous allergic reaction to lidocaine

Design outcomes

Primary

Measure	Time frame	Description
Reduction of pain	Benefit should be seen within first 24 h of infusion	Reduction of pain ≥ 2 points in the numeric pain score after lidocaine infusion treatment. The numeric pain score is a score rating severity of pain from 0 to 10, with higher scores meaning worse pain. The reduction in pain scores indicates a decrease in severity of pain.

Countries

United States

Contacts

CONTACTWilliam L Krogman, MS

wkrogman@kumc.edu316-268-6156

PRINCIPAL_INVESTIGATORFernando Salgado, MD

University of Kansas Medical Center

Outcome results